The effect of vitamin 25-(OH)-D3 on Glucocorticoid Receptor-β (GRβ) and 25-(OH)-D receptors in idiopathic nephrotic syndrome patients

Krisni Subandiyah¹, Harinda Khanifa Khusna²*

ABSTRACT

Background: Idiopathic Nephrotic Syndrome (INS) is the most chronic glomerular disease in children. Glucocorticoid is the main therapy acts by binding to glucocorticoid receptor α (GRα), whereas it is reported that glucocorticoid receptor β (GRβ) is a main inhibitor of GRα. The interaction between glucocorticoid receptors and vitamin D can increase anti-inflammation at glucocorticoid receptors, thereby decreasing GRβ levels. This study was aimed to investigate the effect supplementation of vitamin D3 on GRβ and 25-(OH)-D level in children with INS and the correlation between both of parameters.

Method: A randomized clinical trial, double blind, pre and post-test control group was conducted among 30 subjects with newly diagnosed as INS. Subjects were divided into 2 groups, group 1 (G1) were treated with prednisone and vitamin D3 whereas group 2 (G2) were only treated with prednisone. The level of GRβ and 25-(OH)-D level was measured by ELISA method. Data were analyzed using SPSS version 17 for Windows.

Result: There was significant elevation of 25-(OH)-D plasma between G1 (31.46 ± 9.69 ng/mL) and G2 (13.43±17.25 ng/mL) (p<0.001), and significant decrease of GRβ levels between G1 (-13.71 ± 8.06 ng/mL) and G2 (-0.917 ± 3.76 ng/mL) (p<0.000). Pearson testing first group showed that vitamin D level was positively correlated with GRβ levels (r=0.458; p= 0.01).

Conclusion: The effect supplementation of vitamin D3 can increase 25-(OH)-D level and decrease of GRβ levels significantly in children with idiopathic nephrotic syndrome who receive glucocorticoid therapy.

Keywords: Vitamin 25-(OH)-D3, Glucocorticoid Receptor β, Idiopathic Nephrotic Syndrome

INTRODUCTION

Nephrotic syndrome (SN) is a chronic disease that frequently found in children.¹ The incidence of SN in children is 2-7 new cases per 100,000 children. This disease commonly found in young children with a peak age of 2 to 5 years, and predominantly in male gender (male: female = 2 : 1).² The pathogenesis of idiopathic nephrotic syndrome in children remains unclear, but several hypotheses mention it is due to T-cell dysfunction.³ Glucocorticoids has chosen as first drug therapy in nephrotic syndrome and has function as transcription factors. There are two splicing variants of glucocorticoid receptors, namely glucocorticoid receptor-α (GRα) and glucocorticoid receptors-β (GRβ).⁴ Glucocorticoid receptor-α (GRα) is a classic receptor which triggering the transactivation process. Meanwhile, the glucocorticoid receptor-β (GRβ) does not bind to glucocorticoids but inhibit the GRα. The ability of GRβ to inhibit the action of GRα is thought to have a role in regulating the sensitivity of target cells to glucocorticoids.⁶ Vitamin D is a fat-soluble vitamin consisting of steroid molecules. Cholecalciferol (D3) and cholecalciferol (D2) are two form of vitamin D. In SN, activation of vitamin D receptors (VDR) has a protective effect on podocytes, has limited the activation of renin-angiotensin-aldosterone system, and has an antiproteinuric effect.⁷ Recent studies reveal that the interaction of glucocorticoid receptors and secosteroids hormone receptor (vitamin D hormone) can be affecting glucocorticoid receptors by increasing anti-inflammatory properties of glucocorticoid receptors, thereby reducing GRβ levels. GRβ levels was decrease after vitamin D supplementation to children with low vitamin D levels who was suffering asthma.⁸

Thus far, no research has been reported that evaluates the relationship between supplementation of Vitamin D3 and GRβ levels in children with idiopathic nephrotic syndrome. Therefore, it will be investigated about the effect of giving vitamin D3 supplementation on levels of glucocorticoid
receptors β (GRβ) in idiopathic nephrotic syndrome.

**METHOD**

**Research Design**

An experimental research with double-blind randomized clinical trial (RCT) study design (pre and post-test control group) was done to answer the question study. The study group consisted of two groups: group 1 (G1) was new Idiopathic Nephrotic Syndrome patients who were given oral prednisone and vitamin D3, and group 2 (G2) was new Idiopathic Nephrotic Syndrome patients who were given prednisone alone. Both Vitamin D3 and GRβ levels were measured before and after administration of therapy. Group 1 used prednisone 2 mg/kg/day (maximum dose 80 mg/day) and oral vitamin D3 (D-Vit, PT Gracia Pharmindo TM) 2,000 IU / day for four weeks, while group 2 used prednisone 2 mg/kg/day (maximum dose of 80 mg/day) for four weeks.

A total of 30 subjects participated in this study (15 subjects were G1, and 15 subjects were G2). Subjects were diagnosed with new case of idiopathic nephrotic syndrome who underwent outpatient care at the Children's Nephrology Clinic or were hospitalized in the children's ward RSSA Malang on August 2016 - August 2017. The inclusion criteria were subjects with new idiopathic nephrotic syndrome diagnosis, aged between 1 to 18 years, and the patient's parents allowed their children to be included in the study after being explained (informed consent). Exclusion criteria were secondary nephrotic syndrome patients, nephrotic syndrome patients less than one year old/infantile nephrotic syndrome, relapsed nephrotic syndrome patients and steroid-dependent nephrotic syndrome patients. Drop-out criteria are patients who do not take prednisone or vitamin D3 supplementation recommended by the researcher, and parents or children want to stop following the study.

Blood samples taken from venous blood are collected in centrifuge tubes. The sample was centrifuged for 20 minutes at speed 1,000 times of gravitation (1000G). Then, the plasma was transferred to be checked of 25 (OH) D levels and beta glucocorticoid receptors.

Examination procedure was accordance to ELISA Kit (Alegria Human Vitamin D Kit catalogue number ORG 270). Predilution sample serum (200µl) was added to each well and incubated for 2 hours at 25°C then wash. After washing procedure, 100 µl of the enzyme conjugate was added and incubated for 30 minutes at room temperature. Then, 100ml of chromogen/substrate was added and incubated for 15 minutes at room temperature without being shaken and protected from direct sunlight. Finally, 100 µl of stopping solution was added to each well. The blue colour's of the absorbance intensity was read at 650 nm spectrophotometrically. Vitamin D levels are categorized as deficiency if serum 25 (OH) D levels > 20 ng / ml, insufficiency if 10-20 ng / ml and deficiency if <10 ng / ml.

The reagents were prepared according to the procedure from the kit manufacturer (Mybiosource Cat # MBS0396666). A total of 50 µL assay diluents were put into each well. Then 200 µL of the standard solution or sample examined is added. Then the plates were covered and incubated for 3 hours at room temperature. Then the washing process was performed, the liquid in the well was discharged, the remaining liquid was dried by turning and pressing the surface of the plate on tissue paper. A total of 400 µL of washing buffer solution was put into the well and then removed. This washing procedure was carried out 3 times. Two hundred µL glucocorticoid conjugates β were added to each well, then covered and incubated for 2.5 hours at room temperature. After that, the washing process was carried out again. A total of 50 µL substrate was added, then covered and incubated for 1 hour at room temperature. Then 50 µL stop solution was added. Optical density (OD) must be measured within 30 minutes using a microplate reader (Biorad 520 with a wavelength of 450 nM).

The normality of sample data was tested using the Kolmogorov-Smirnov test. The decision criteria are if the p-value was greater than 0.05, then the data is normally distributed. Differences in GRβ levels, plasma vitamin 25 (OH) D levels were performed by independent T-tests. The relationship of GRβ levels with plasma vitamin 25 (OH) D levels was performed by Pearson correlation test. Data were analyzed using 95% confidence level (α = 0.05). All calculations were done with SPSS for Windows 17.

**RESULT**

During fourt weeks observation and treatment period, no subjects were found to be sick or affected by side effects due to the use of prednisone or vitamin D3. The subject's essential characteristics such as age, sex, vitamin D status and nutritional status are shown in Table 1. Clinical outcomes in the subjects appear in Table 2, which shows that in G1, more patients experienced remission before four weeks of therapy (13/30) compared to G2 (6/30).

The comparative test result levels of 25 (OH) D explained that there were significant differences in plasma vitamin 25 (OH) D levels between the treatment groups of prednisone + vitamin D3 exposure (31.46 ± 9.69 ng / mL) and the group of
The correlation test results showed that there was a significant relationship or correlation between decreased GRβ levels with increased plasma vitamin 25 (OH) D levels (r= -0.458; p = 0.01) in pediatric patients diagnosed with idiopathic nephrotic syndrome with exposure to prednisone + vitamin D3 (Table 5).

DISCUSSION
The most distribution is obtained at the age of fewer than ten years (27 subjects). This is consistent with previous epidemiological data that 75% of SNI’s are less than 10 years old. Gender is found that male dominant than female. Comparison of male-dominated incidents with a 2: 1 ratio. The Higher prevalence in boys is thought to be related to abnormal T-cell clones that often occur in boys’ thymus glands.

The results of clinical examination of nutritional status are mostly in good nutritional condition, but children with SNI are very at risk of experiencing growth disorders so that nutritional evaluation must be carried out regularly. The results of this study found 21 out of 30 SNI subjects had low vitamin D levels, similar to research in Jakarta which reported that 22 of the 26 SNI subjects had low vitamin D levels. In SN, where leakage of albumin filtration occurs in the glomerulus, DBG (vitamin D-binding globulin) leakage also occurs, which has a smaller molecular weight than albumin. This leakage results in a decrease of 25 (OH) D concentration in circulation. In a study by Nielsen et al., it was found that 93% of children with SN had vitamin D deficiency at the start of diagnosis and 25 (OH) D levels were positively correlated with plasma albumin. Thus, vitamin D has been shown to be important in the pathogenesis of autoimmune diseases such as SN.

A significant difference was found in the difference average in levels of 25 (OH) D plasma in G1 (31.46 ± 9.69 ng / mL) and G2 (13.43 ± 17.25 ng / mL) (p = 0.001). Vitamin D3 that given as adjuvant therapy in this study will then be absorbed in the intestine and then transported into the blood through vitamin D binding protein (DBP). In the liver, hydroxylated vitamin D results in the formation of 25-hydroxyvitamin D3 (25 (OH) D) which is the most common form of vitamin D in plasma. So this explains that the administration of vitamin D therapy can increase levels of 25 (OH) D in plasma.

In this study, a significant difference result was found in the GRβ levels (p = 0.000) between G1 (-13.71 ± 8.06) and to G2 (-0.917 ± 3.76). This result shows that the administration of prednisone plus
**Vitamin D in its active form (calcitriol) interacts with VDR (vitamin D receptor). In the cytoplasm, vitamin D3 binds to its receptors and forms a heterodimer with a retinoid X-receptor (RXR), which in turn translocate to the nucleus. In the nucleus, the VDR-RXR complex will bind to VDRE. This bond will then attract co-activators and enzymes through histone acetylation activity, causing structural changes in chromatin that will trigger gene transcription.**

Various studies have shown that vitamin D can increase the action of glucocorticoids by increasing the anti-inflammatory activity of glucocorticoids. In research, vitamin D has been shown to increase the expression of MKP-1 mRNA by cells through an increase in GR binding to MKP-1 promoters resulting in an increase in transcription of IL-10 and MKP-1 anti-inflammatory protein genes (mitogen-activated protein kinase phosphatase-1) mediated by glucocorticoid bonds with GR. Induction of IL-10 and MKP-1 production is known to increase the anti-inflammatory function of glucocorticoids and increase cell sensitivity to glucocorticoids.

**RESEARCH LIMITATIONS**

Vitamin D3 supplementation was not distinguished between subjects with normal plasma vitamin 25 (OH) D levels, insufficiency or deficiency, factors affecting changes in vitamin D levels such as high nutrient intake of vitamin D such as milk, or levels of exposure to sunlight, settlement which is inhabited by patients can also be a confounding factor so that it can affect the results of the study, other biomolecular factors that have not been studied in this study include levels of glucocorticoid receptors α (GRα) and vitamin D receptors (VDR).

**CONCLUSION**

Supplementation of vitamin D3 can increase levels of 25 (OH) D and reduce levels of GRβ in SNI children receiving corticosteroid therapy.

**CONFLICT OF INTEREST**

The authors confirm there are no conflict of interest during study procedure and publish procedure.

**FUNDING**

This research was funded privately by authors.

**ETHICAL CLEAREANCE**

This research was conducted after obtaining approval from the ethics commission RSAA Malang Research.
AUTHOR CONTRIBUTION

All authors contributed to the process of this research.

REFERENCES